TRAF6 and in situ carcinoma: It will be interesting to investigate the consequence of FGF1 overexpression on TRAF6 activity in our COV434-FGF1 cells but also in A2780-CIS cells that resist cisplatin and overexpress FGF1 in comparison to A2780 cisplatin sensitive cells8.